Born to survive: how cancer cells resist CAR T cell therapy

Authors: Jean Lemoine, Marco Ruella, Roch Houot

Published: 2021-11-22

DOI: 10.1186/s13045-021-01209-9

Source: Full article

---

Abstract

AbstractAlthough chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.